drugset / Trial / NCT05338502
Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants
Non-randomizedSequentialOpen-labelBasic science
Summary
The main purpose of this study is to learn about how H2 antagonist (ranitidine) and proton pump inhibitor (PPI) (omeprazole) affect Selpercatinib in healthy participants. Information about safety and tolerability will be collected. The study will last up to about 9 weeks, inclusive of screening period.
Timeline
- Start
- 2019-07-08
- Primary completion
- 2019-09-03
- Completion
- 2019-09-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omeprazole | Other / unclassified | 40 mg | Oral |
| Subject | Ranitidine | Unknown | 150 mg | Oral |
| Subject | Selpercatinib | Small molecule | 160 mg | Oral |
Indications
No indication recorded.